Pharmaceuticals(IN20320.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
Pharmaceuticals
IN20320.HK
News
View More

CSPC PHARMA's subsidiary, CSPC Innovation, reported a loss of at least 170 million RMB last year

CSPC PHARMA's subsidiary, CSPC Innovation, issued a profit warning, expecting a loss of between 170 million and 250 million RMB for the fiscal year 2025, compared to a profit of 53.73 million RMB in the previous year. The reasons for the loss include an increase in R&D expenses to approximately 1 billion RMB, the acquisition of a minority stake in the controlling subsidiary, Jushi Biotech, leading to a greater impact on net profit, and a decrease in the gross profit margin of the functional raw materials business

AASTOCKS·
HK
01093
-0.10%
AASTOCKS·
HK
01093
-0.10%

China NT Pharma Group Co. Ltd. Held Extraordinary General Meeting

China NT Pharma Group Co. Ltd. held an extraordinary general meeting on January 15, 2026, where shareholders approved the issuance of up to 274,751,679 shares for the acquisition of 100% of Junbinxiongdi Limited, Yuehua Limited, and Zhong He Qun Lian Limited. This acquisition grants control of approximately 58.11% of Zhejiang Kangyuan Medical Device Co., Ltd. All proposals at the meeting were approved.

Reuters·
HK
01011
-3.49%
Reuters·
HK
01011
-3.49%

In "Major Banks," China International Capital Corporation (CICC) stated that the acquisition of SINO BIOPHARM could enhance the layout in the weight loss metabolism field, maintaining a target price of 8.9 yuan

CICC released a research report stating that SINO BIOPHARM acquired Hegia Biotech for RMB 1.2 billion, focusing on weight loss metabolism, cardiovascular, and nervous system fields. This acquisition will help SINO BIOPHARM build an innovative pipeline for cardiovascular treatments to meet clinical needs in the chronic disease sector. CICC maintains its net profit forecasts for 2025 and 2026, and introduces a forecast for 2027, with a target price of HKD 8.9 and a rating of "outperform the industry."

AASTOCKS·
HK
01177
-1.55%
AASTOCKS·
HK
01177
-1.55%

CF PharmTech Repurchases 12,000 Shares for HKD 384,140 in HKEX Filing

CF PharmTech Inc. has announced the repurchase of 12,000 shares for a total of HKD 384,140, as disclosed in a filing with the Hong Kong Stock Exchange. The repurchased shares will be held as treasury shares. This information is part of a next day disclosure return.

Reuters·
HK
02652
+2.64%
Reuters·
HK
02652
+2.64%

Hutchmed China hails lung cancer trial results published in Lancet

Hutchmed China Ltd announced that results from its SACHI phase-three lung cancer trial have been published in The Lancet. The trial studied the combination of savolitinib and osimertinib for treating advanced non-small cell lung cancer with MET amplification. This is the first randomized phase three trial confirming the efficacy of MET inhibition in this patient group. The combination was approved in China last June. Shares of Hutchmed China fell 0.5% to 220.00 pence following the announcement.

marketscreener·
HK
00013
+2.13%
US
HCM
+0.07%
marketscreener·
HK
00013
+2.13%
US
HCM
+0.07%
Posts
View More

$VIGONVITA-B(02630.HK)definitely go up

© 2026 Longbridge｜Disclaimer